The human chromosome 19q13.32 is a gene rich region and has been associated with multiple phenotypes, including late onset Alzheimer’s disease (LOAD) and other age-related conditions.
Objective:
Here we developed the first humanized mouse model that contains the entire TOMM40 and APOE genes with all intronic and intergenic sequences including the upstream and downstream regions. Thus, the mouse model carries the human TOMM40 and APOE genes and their intact regulatory sequences.
Methods:
We generated the APOE-TOMM40 humanized mouse model in which the entire mouse region was replaced with the human (h)APOE-TOMM40 loci including their upstream and downstream flanking regulatory sequences using recombineering technologies. We then measured the expression of the human TOMM40 and APOE genes in the mice brain, liver, and spleen tissues using TaqMan based mRNA expression assays.
Results:
We investigated the effects of the ‘523’ polyT genotype (S/S or VL/VL), sex, and age on the human TOMM40- and APOE-mRNAs expression levels using our new humanized mouse model. The analysis revealed tissue specific and shared effects of the ‘523’ polyT genotype, sex, and age on the regulation of the human TOMM40 and APOE genes. Noteworthy, the regulatory effect of the ‘523’ polyT genotype was observed for all studied organs.
Conclusion:
The model offers new opportunities for basic science, translational, and preclinical drug discovery studies focused on the APOE genomic region in relation to LOAD and other conditions in adulthood.
SaxenaR, VoightBF, LyssenkoV, BurttNP, de BakkerPI, ChenH, RoixJJ, KathiresanS, HirschhornJN, DalyMJ (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science316, 1331–1336.
2.
AulchenkoYS, RipattiS, LindqvistI, BoomsmaD, HeidIM, PramstallerPP, PenninxBW, JanssensACJ, WilsonJF, SpectorT (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet41, 47.
3.
TeslovichTM, MusunuruK, SmithAV, EdmondsonAC, StylianouIM, KosekiM, KathiresanS (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature466, 707–713.
4.
KettunenJ, TukiainenT, SarinAP, Ortega-AlonsoA, TikkanenE, LyytikäinenLP, RipattiS (2012) Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet44, 269–276.
5.
LiYJ, NuytemansK, LaJO, JiangR, SliferSH, SunS, NajA, GaoXR, MartinER (2023) Identification of novel genes for age-at-onset of Alzheimer’s disease by combining quantitative and survival trait analyses. Alzheimers Dement doi: 10.1002/alz.12927.
6.
CoonKD, MyersAJ, CraigDW, WebsterJA, PearsonJV, LinceDH, StephanDA (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry68, 613–618.
7.
GrupeA, AbrahamR, LiY, RowlandC, HollingworthP, MorganA, WilliamsJ (2007) Evidence for novel susceptibility genes for late-onset Alzheimer’s disease from a genome-wide association study of putative functional variants. Hum Mol Genet16, 865–873.
8.
ErnoultE, GamelinE, GuetteC (2008) Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Sci6, 27.
9.
AbrahamR, MoskvinaV, SimsR, HollingworthP, MorganA, GeorgievaL, KirovG (2008) A genome-wide association study for late-onset Alzheimer’s disease using DNA pooling. BMC Med Genomics1, 44.
10.
BertramL, LangeC, MullinK, ParkinsonM, HsiaoM, HoganMF, TanziRE (2008) Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genet83, 623–632.
11.
BeechamGW, MartinER, LiYG, SliferMA, GilbertJR, HainesJL, Pericak-VanceMA (2009) Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet84, 35–43.
12.
CarrasquilloMM, ZouF, PankratzVS, WilcoxSL, MaL, WalkerLP, YounkinSG (2009) Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease. Nat Genet41, 192–198.
13.
HaroldD, AbrahamR, HollingworthP, SimsR, GerrishA, HamshereML, WilliamsJ (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet41, 1088–1093.
14.
LambertJC, HeathS, EvenG, CampionD, SleegersK, HiltunenM, AmouyelP (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet41, 1094–1099.
15.
PotkinSG, GuffantiG, LakatosA, TurnerJA, KruggelF, FallonJH, MacciardiF (2009) Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer’s disease. PLoS One4, e6501.
16.
HeinzenEL, NeedAC, HaydenKM, Chiba-FalekO, RosesAD, StrittmatterWJ, GoldsteinDB (2010) Genome-wide scan of copy number variation in late-onset Alzheimer’s disease. J Alzheimers Dis19, 69–77.
17.
SeshadriS, FitzpatrickAL, IkramMA, DeStefanoAL, GudnasonV, BoadaM, BretelerMM (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA303, 1832–1840.
18.
KambohMI, BarmadaMM, DemirciFY, MinsterRL, CarrasquilloMM, PankratzVS, LopezOL (2012) Genome-wide association analysis of age-of-onset in Alzheimer’s disease. Mol Psychiatry17, 1340–1346.
19.
LyallDM, HarrisSE, BastinME, ManiegaSM, MurrayC, LutzMW, DearyIJ (2014) Are APOE ɛ3 genotype and TOMM40 poly-T repeat length associations with cognitive ageing mediated by brain white matter integrity?Transl Psychiatry4, e449.
20.
NebelA, KleindorpR, CaliebeA, NothnagelM, BlanchéH, JungeO, SchreiberS (2011) A genome-wide association study confirms APOE as the major gene influencing survival in long-lived individuals. Mech Ageing Dev132, 324–330.
21.
SmithEN, ChenW, KähönenM, KettunenJ, LehtimäkiT, PeltonenL, MurraySS (2010) Longitudinal genome-wide association of cardiovascular risk factors in the Bogalusa heart study. PLoS Genet6, e1001094.
22.
MiddelbergRP, FerreiraMA, HendersAK, HeathAC, MaddenPA, MontgomeryGW, MartinNG, WhitfieldJB (2011) Genetic variants in LPL, OASL, and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med Genet12, 123.
23.
SuchindranS, RivedalD, GuytonJR, MilledgeT, GaoX, BenjaminA, RowellJ, GinsburgGS, McCarthyJJ (2010) Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet6, e1000928.
24.
GrallertH, DupuisJ, BisJC, DehghanA, BarbalicM, BaumertJ, LuC, SmithNL, UitterlindenAG, RobertsR, KhuseyinovaN, SchnabelRB, RiceKM, RivadeneiraF, HoogeveenRC, FontesJD, MeisingerC, KeaneyJF Jr, LemaitreR, AulchenkoYS, VasanRS, EllisS, HazenSL, vanDuijn CM, NelsonJJ, MärzW, SchunkertH, McPhersonRM, Stirnadel-FarrantHA, PsatyBM, GiegerC, SiscovickD, HofmanA, IlligT, CushmanM, YamamotoJF, RotterJI, LarsonMG, StewartAF, BoerwinkleE, WittemanJC, TracyRP, KoenigW, BenjaminEJ, BallantyneCM (2012) Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: Meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J33, 238–251.
25.
Chiba-FalekO, LinnertzC, GuytonJ, GardnerSD, RosesAD, McCarthyJJ, PatelK (2012) Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet131, 1911–1920.
26.
YangA, KantorB, Chiba-FalekO (2021) APOE: The new frontier in the development of a therapeutic target towards precision medicine in late-onset Alzheimer’s. Int J Mol Sci22, 1244.
27.
GottschalkWK, MihovilovicM, RosesAD, Chiba-FalekO (2016) The role of upregulated APOE in Alzheimer’s disease etiology. J Alzheimers Dis Parkinsonism6, 209.
28.
NuytemansK, Lipkin VasquezM, WangL, Van BoovenD, GriswoldAJ, RajabliF, CelisK, OronO, HofmannN, RolatiS, Garcia-SerjeC, ZhangS, JinF, ArgenzianoM, GrantSFA, ChesiA, BrownCD, YoungJI, DykxhoornDM, Pericak-VanceMA, VanceJM (2022) Identifying differential regulatory control of APOE varepsilon4 on African versus European haplotypes as potential therapeutic targets. Alzheimers Dement18, 1930–1942.
29.
PaytonA, SindrewiczP, PessoaV, PlattH, HoranM, OllierW, BubbVJ, PendletonN, QuinnJP (2016) A TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpathologic aging. Neurobiol Aging39, 217.e1–7.
30.
LinnertzC, AndersonL, GottschalkW, CrenshawD, LutzMW, AllenJ, SaithS, MihovilovicM, BurkeJR, Welsh-BohmerKA, RosesAD, Chiba-FalekO (2014) The cis-regulatory effect of an Alzheimer’s disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. Alzheimers Dement10, 541–551.
31.
ForakerJ, MillardSP, LeongL, ThomsonZ, ChenS, KeeneCD, BekrisLM, YuCE (2015) The APOE gene is differentially methylated in Alzheimer’s disease. J Alzheimers Dis48, 745–755.
32.
ShaoY, ShawM, ToddK, KhrestianM, D’AleoG, BarnardPJ, ZahratkaJ, PillaiJ, YuCE, KeeneCD, LeverenzJB, BekrisLM (2018) DNA methylation of TOMM40-APOE-APOC2 in Alzheimer’s disease. J Hum Genet63, 459–471.
NakashimaY, PlumpAS, RainesEW, BreslowJL, RossR (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb14, 133–140.
37.
PeiY, JiangR, ZouY, WangY, ZhangS, G.WangG, ZhaoJ, SongW (2016) Effects of fine particulate matter (PM2.5) on systemic oxidative stress and cardiac function in ApoE(-/-) mice. Int J Environ Res Public Health13, E484.
38.
ZhouQ, ZhaoF, Ze-PingL, ZhengC, ZhengW, SunL, YangZ (2014) Association between APOC1 polymorphism and Alzheimer’s disease: A case-control study and meta-analysis. PLoS One9, e87017.
39.
SubramanianS, GottschalkWK, KimSY, RosesAD, Chiba-FalekO (2017) The effects of PPARγ on the regulation of the TOMM40-APOE-C1 genes cluster. Biochim Biophys Acta Mol Basis Dis1863, 810–816.
40.
BekrisLM, LutzF, YuC-E (2012) Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. J Hum Genet57, 18–25.
41.
LinnertzC, SaucierL, GeD, CroninKD, BurkeJR, BrowndykeJN, HuletteCM, Welsh-BohmerKA, Chiba-FalekO (2009) Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One4, e7480.
42.
SullivanPM, MezdourH, ArataniY, KnouffC, NajibJ, ReddickRL, QuarfordtSH, MaedaN (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem272, 17972–17980.
43.
GamacheJ, YunY, Chiba-FalekO (2020) Sex-dependent effect of APOE on Alzheimer’s disease and other age-related neurodegenerative disorders. Dis Model Mech13, dmm045211.
44.
HogervorstE, TempleS, O’DonnellE (2023) Sex differences in dementia. Curr Top Behav Neurosci62, 309–331.
45.
RosesAD (2010) An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch Neurol67, 536–541.
46.
RosesAD, LutzMW, Amrine-MadsenH, SaundersAM, CrenshawDG, SundsethSS, HuentelmanMJ, Welsh-BohmerKA, ReimanEM (2010) A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer’s disease. Pharmacogenomics J10, 375–384.
47.
TuranS, ZeheC, KuehleJ, QiaoJ, BodeJ (2013) Recombinase-mediated cassette exchange (RMCE) - a rapidly-expanding toolbox for targeted genomic modifications. Gene515, 1–27.
48.
GrehanS, TseE, TaylorJM (2001) Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci21, 812–822.
49.
ShihS-J, AllanC, GrehanS, TseE, MoranC, TaylorJM (2000) Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem275, 31567–31572.
50.
LinnertzC, SaundersAM, LutzMW, CrenshawDM, GrossmanI, BurnsDK, WhitfieldKE, HauserMA, McCarthyJJ, UlmerM, AllinghamR, Welsh-BohmerKA, RosesAD, Chiba-FalekO (2012) Characterization of the poly-T variant in the TOMM40 gene in diverse populations. PLoS One7, e30994.
51.
KochW, EhrenhaftA, GriesserK, PfeuferA, MullerJ, SchomigA, KastratiA (2002) TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med40, 1123–1131.
52.
DE H, Baseline life span data: Commonly used JAX Mice and crosses (Study 1),The Jackson Laboratory, http://research.jax.org/faculty/harrison/ger1vi_LifeStudy1.html, November 11, 2011, Accessed 25 January. 2023.
53.
ZarowC, VictoroffJ (1998) Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol149, 79–86.
54.
MatsuiT, IngelssonM, FukumotoH, RamasamyK, KowaH, FroschMP, IrizarryMC, HymanBT (2007) Expression of APP pathway mRNAs and proteins in Alzheimer’s disease. Brain Res1161, 116–123.
55.
AkramA, SchmeidlerJ, KatselP, HofPR, HaroutunianV (2012) Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging33, 628.e1-628.e14.
56.
GrubmanA, ChewG, OuyangJF, SunG, ChooXY, McLeanC, SimmonsRK, BuckberryS, Vargas-LandinDB, PoppeD, PfluegerJ, ListerR, RackhamOJL, PetrettoE, PoloJM (2019) A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. Nat Neurosci22, 2087–2097.
HashemiaghdamA, MroczekM (2020) Microglia heterogeneity and neurodegeneration: The emerging paradigm of the role of immunity in Alzheimer’s disease. J Neuroimmunol341, 577185.
59.
ZhengJY, SunJ, JiCM, ShenL, ChenZJ, XieP, SunYZ, YuRT (2017) Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer’s disease (APP/PS1) mice by inhibiting TGF-beta/Smad2/STAT3 signaling. Neurobiol Aging54, 112–132.
60.
Bien-LyN, GillespieAK, WalkerD, YoonSY, HuangY (2012) Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci32, 4803–4811.
61.
KimJ, JiangH, ParkS, EltoraiAE, StewartFR, YoonH, BasakJM, FinnMB, HoltzmanDM (2011) Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci31, 18007–18012.
62.
HuynhTV, LiaoF, FrancisCM, RobinsonGO, SerranoJR, JiangH, RohJ, FinnMB, SullivanPM, EsparzaTJ, StewartFR, MahanTE, UlrichJD, ColeT, HoltzmanDM (2017) Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of beta-amyloidosis. Neuron96, 1013-1023 e1014.
63.
SimonetWS, BucayN, PitasRE, LauerSJ, TaylorJM (1991) Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J Biol Chem266, 8651–8654.
64.
SimonetWS, BucayN, LauerSJ, TaylorJM (1993) A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem268, 8221–8229.
65.
TaylorJM, SimonetWS, LauerSJ, ZhuG, WalkerD (1993) Regulation and expression of the human apolipoprotein E gene in transgenic mice. Curr Opin Lipidol4, 84–89.
66.
KlosK, ShimminL, BallantyneC, BoerwinkleE, ClarkA, CoreshJ, HanisC, LiuK, SayreS, HixsonJ (2008) APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Hum Mol Genet17, 2039–2046.
67.
ZhengP, PennacchioLA, Le GoffW, RubinEM, SmithJD (2004) Identification of a novel enhancer of brain expression near the apoE gene cluster by comparative genomics. Biochim Biophys Acta1676, 41–50.
68.
RamosMC, MatíasS, ArtigaMJ, PozuetaJ, SastreI, ValdiviesoF, BullidoMJ (2005) Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter. Neuroreport16, 1027–1030.
69.
BekrisLM, GallowayNM, MontineTJ, SchellenbergGD, YuC-E (2010) APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet153B, 409–417.
70.
YuC-E, CudabackE, ForakerJ, ThomsonZ, LeongL, LutzF, GillJA, SaxtonA, KraemerB, NavasP, KeeneD, MontineT, BekrisLM (2013) Epigenetic signature and enhancer activity of the human APOE gene. Hum Mol Genet22, 5036–5047.
71.
MapstoneM, GrossTJ, MacciardiF, CheemaAK, PetersenM, HeadE, HandenBL, KlunkWE, ChristianBT, SilvermanW (2020) Metabolic correlates of prevalent mild cognitive impairment and Alzheimer’s disease in adults with Down syndrome. Alzheimers Dement (Amst)12, e12028.
72.
Martinez-MartinezAB, Torres-PerezE, DevanneyN, Del MoralR, JohnsonLA, Arbones-MainarJM (2020) Beyond the CNS: The many peripheral roles of APOE. Neurobiol Dis138, 104809.
ZhengH, CaiA, ShuQ, NiuY, XuP, LiC, LinL, GaoH (2018) Tissue-specific metabolomics analysis identifies the liver as a major organ of metabolic disorders in amyloid precursor protein/presenilin 1 mice of Alzheimer’s disease. J Proteome Res18, 1218–1227.
75.
ZhangX, TongT, ChangA, AngTFA, TaoQ, AuerbachS, DevineS, QiuWQ, MezJ, MassaroJ (2023) Midlife lipid and glucose levels are associated with Alzheimer’s disease. Alzheimers Dement19, 181–193.
76.
ZhuY, LiuX, ZhuR, ZhaoJ, WangQ (2022) Lipid levels and the risk of dementia: A dose–response meta-analysis of prospective cohort studies. Ann Clin Transl Neurol9, 296–311.
77.
GiannisisA, PatraK, EdlundAK, NietoLA, Benedicto-GrasJ, MoussaudS, de la RosaA, TwohigD, BengtssonT, FuY, BuG, BialG, FoquetL, HammarstedtC, StromS, KannistoK, RaberJ, EllisE, NielsenHM (2022) Brain integrity is altered by hepatic APOE epsilon4 in humanized-liver mice. Mol Psychiatry27, 3533–3543.
78.
KesslerK, GiannisisA, BialG, FoquetL, NielsenHM, RaberJ (2023) Behavioral and cognitive performance of humanized APOEepsilon3/epsilon3 liver mice in relation to plasma apolipoprotein E levels. Sci Rep13, 1728.
79.
CarranoA, HoozemansJJ, van der ViesSM, RozemullerAJ, van HorssenJ, de VriesHE (2011) Amyloid beta induces oxidative stress-mediated blood–brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal15, 1167–1178.
80.
EricksonMA, BanksWA (2013) Blood–brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab33, 1500–1513.
81.
TogoT, AkiyamaH, IsekiE, KondoH, IkedaK, KatoM, OdaT, TsuchiyaK, KosakaK (2002) Occurrence of T cells in the brain of Alzheimer’s disease and other neurological diseases. J Neuroimmunol124, 83–92.
HuangL-T, ZhangC-P, WangY-B, WangJ-H (2022) Association of peripheral blood cell profile with Alzheimer’s disease: A meta-analysis. Front Aging Neurosci14, 888946.
